GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.

Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I, Moreno P, Mariñoso ML, Esbrit P, Villanueva-Peñacarrillo ML

The Journal of endocrinology3 Mar 2011Cited by 79 (Europe PMC)

PMID21372151DOI10.1530/joe-11-0015PepBankPUB-21372151

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 decreased plasma glucose compared with control.
In plain wordsIn rats with high blood lipids, exendin‑4 reduced blood sugar compared with control.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma glucose
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215101
02AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 decreased plasma triglycerides compared with control.
In plain wordsIn rats with high blood lipids, exendin‑4 reduced blood triglycerides compared with control.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma triglycerides
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215102
03AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 decreased plasma total cholesterol compared with control.
In plain wordsIn rats with high blood lipids, exendin‑4 reduced blood cholesterol compared with control.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma total cholesterol
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215103
04AnimalAnimal study (in vivo)Mechanism
In hyperlipidic rats, exendin‑4 increased tibial osteocalcin gene expression above control values.
In plain wordsIn rats with high blood lipids, exendin‑4 increased bone osteocalcin gene expression above control values.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOsteocalcin gene expression
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma but increased osteocalcin (OC) gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio - at the expense of an augmented OPG - above corresponding contro…
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215104
05AnimalAnimal study (in vivo)Mechanism
In hyperlipidic rats, exendin‑4 increased the tibial OPG/RANKL ratio above control values.
In plain wordsIn rats with high blood lipids, exendin‑4 increased the bone OPG/RANKL ratio above control values.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOPG/RANKL ratio
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma but increased osteocalcin (OC) gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio - at the expense of an augmented OPG - above corresponding contro…
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215105
06AnimalAnimal study (in vivo)Mechanism
In hyperlipidic rats, exendin‑4 augmented tibial OPG above control values.
In plain wordsIn rats with high blood lipids, exendin‑4 increased bone OPG above control values.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOPG
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma but increased osteocalcin (OC) gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio - at the expense of an augmented OPG - above corresponding contro…
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215106
07AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 reversed decreased femoral bone mass.
In plain wordsIn rats with high blood lipids, exendin‑4 reversed the reduction in thigh bone mass compared with saline control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFemoral bone mass
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling.
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215107
08AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 reversed decreased vertebral bone mass.
In plain wordsIn rats with high blood lipids, exendin‑4 reversed the reduction in spine bone mass compared with saline control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseVertebral bone mass
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling.
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215108
09AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 improved deteriorated vertebral trabecular structure.
In plain wordsIn rats with high blood lipids, exendin‑4 improved damaged spine bone structure compared with saline control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseVertebral trabecular structure
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling.
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215109
10AnimalAnimal study (in vivo)Efficacy outcome
In hyperlipidic rats, exendin‑4 treatment was associated with normalization of bone remodeling.
In plain wordsIn rats with high blood lipids, exendin‑4 treatment was linked to normalized bone remodeling compared with saline control.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableBone remodeling
Study
ratn: not reported in source
Hyperlipidic Wistar rats
Comparator
Saline control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 nmol/kg per h · subcutaneous continuous infusion · 3 daysAs given in this study (rat).
Source sentences
Summary
Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling.
1 context sentence(design, population, supporting numbers)
Summary · context
Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days.
Report a problemFND-2137215110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02473809

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

University of Aarhusn = 60Aug 2015 to Oct 2017

Diabetes Complications · Osteoporosis

Trial page ClinicalTrials.govUpdated 26 Sept 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.